跳至主要内容
临床试验/NCT05764642
NCT05764642Enrolling By Invitation2 期

Renal Microvessel Imaging for Characterization of Chronic Kidney Disease

Mayo Clinic4 个研究点 分布在 1 个国家目标入组 186 人开始时间: 2023年8月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
Enrolling By Invitation
发起方
Mayo Clinic
入组人数
186
试验地点
4
主要终点
Renal cortex microvessel diameter

研究概览

简要总结

The purpose of this research is to study the efficacy of ultrasound microvessel imaging for evaluation of Chronic Kidney Disease. Definity is an ultrasound contrast agent currently approved by the FDA for use on the heart, liver, and urinary tract. This study will look at its effectiveness on the kidney.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • - Healthy volunteers or Chronic Kidney Disease (CKD) patients with clinically indicated renal biopsy.

排除标准

  • Subjects lacking capacity to consent.
  • Vulnerable subjects such as prisoners; pregnant women; nursing mother.
  • Subjects with history of hypersensitivity allergic reactions to ultrasound contrast agents.
  • Patients with high-risk cardiac diseases.

研究组 & 干预措施

Chronic Kidney Disease Group

Experimental

Subjects with Chronic Kidney Disease (CKD) with clinically indicated renal biopsy will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent.

干预措施: Definity (Drug)

Healthy Control Group

Active Comparator

Healthy volunteers with normal eGFR will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent.

干预措施: Definity (Drug)

Chronic Kidney Disease Group

Experimental

Subjects with Chronic Kidney Disease (CKD) with clinically indicated renal biopsy will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent.

干预措施: Super-resolution ultrasound imaging (Diagnostic Test)

Healthy Control Group

Active Comparator

Healthy volunteers with normal eGFR will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent.

干预措施: Super-resolution ultrasound imaging (Diagnostic Test)

结局指标

主要结局

Renal cortex microvessel diameter

时间窗: Baseline

Super-Resolution Ultrasound Imaging (SRUI) parameters reported in millimeters (mm)

Renal blood flow velocity

时间窗: Baseline

Super-Resolution Ultrasound Imaging (SRUI) parameters reported in centimeters per second (cm/sec)

Renal cortex microvessel density

时间窗: Baseline

Super-Resolution Ultrasound Imaging (SRUI) parameters reported in percentage

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Shigao Chen

Principal Investigator

Mayo Clinic

研究点 (4)

Loading locations...

相似试验